Financial statements Novo Nordisk Pharma
Cash flow statement of Novo Nordisk Pharma
Company age:
Age:
23 y. 7 m. 16 d.
Share capital:
Share capital:
29 021 000 PLN
Cash inflows of NOVO NORDISK PHARMA
|
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
|---|---|---|---|---|---|---|
| Net cash from operating expenses | -3 952 700,50 | 397 145,44 | 12 057 451,16 | -1 856 224,40 | -8 971 502,75 | 10 828 412,19 |
| Net cash flow from investing activities | -3 318 125,20 | -147 781,04 | -293 306,76 | 0,00 | 0,00 | -717 080,00 |
| Net cash flow from financial activities | 3 101 029,18 | -297 816,73 | -2 803 212,45 | 0,00 | 2 281 499,90 | -2 281 499,90 |
| Total net cash flow | -4 169 796,52 | -48 452,33 | 8 960 931,95 | -1 856 224,40 | -6 690 002,85 | 7 829 832,29 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.